Dossier assessment
Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Edoxaban: considerable added benefit for certain patients
Additional information
IQWiG health information
Anticoagulants are medicines that prevent blood clots from forming in the bloodstream. This reduces the risk of medical problems that are caused by blood clots – such as heart attacks, strokes and thrombosis.
Federal Joint Committee (G-BA)
2016-01-21 A G-BA decision was published.
Project details
- Project no.
- A15-29
- Commission
- Commission awarded on 20.07.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.